This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jones, R. N. Articles by Sheehan, D. J. Search for Related Content PubMed PubMed Citation Articles by Jones, R. N. Articles by Sheehan, D. J.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, July 2006, p. 2622-2625, Vol. 44, No. 7
0095-1137/06/$08.00+0     doi:10.1128/JCM.00576-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Selection of a Surrogate Agent (Vancomycin or Teicoplanin) for Initial Susceptibility Testing of Dalbavancin: Results from an International Antimicrobial Surveillance Program

JMI Laboratories, North Liberty, Iowa,¹ Tufts University School of Medicine, Boston, Massachusetts,² Pfizer Inc., New York, New York³

Received 17 March 2006/ Returned for modification 26 April 2006/ Accepted 11 May 2006

The immediate lack of market-dominating commercial products (Vitek or MicroScan) for susceptibility testing of the new glycolipopeptide, dalbavancin, requires a surrogate marker agent to assist microbiologists in the correct categorization of potentially indicated species (staphylococci and streptococci). Error-rate analyses for 16,749 isolates using vancomycin or teicoplanin results to categorize dalbavancin susceptibilities demonstrated that both glycopeptide agents were highly predictive of dalbavancin-susceptible results (nearly 100%) with only a rare minor error. Vancomycin test results most reliably predict dalbavancin susceptibility until validated commercial reagents become available for direct testing in clinical practice.

This article has been cited by other articles:

• Pfaller, M. A., Messer, S. A., Boyken, L., Tendolkar, S., Hollis, R. J., Diekema, D. J. (2008). Selection of a Surrogate Agent (Fluconazole or Voriconazole) for Initial Susceptibility Testing of Posaconazole against Candida spp.: Results from a Global Antifungal Surveillance Program. J. Clin. Microbiol. 46: 551-559 [Abstract] [Full Text]  
• Biedenbach, D. J., Ross, J. E., Fritsche, T. R., Sader, H. S., Jones, R. N. (2007). Activity of Dalbavancin Tested against Staphylococcus spp. and {beta}-Hemolytic Streptococcus spp. Isolated from 52 Geographically Diverse Medical Centers in the United States. J. Clin. Microbiol. 45: 998-1004 [Abstract] [Full Text]